EGFR and lung cancer: Other EGFR mutations in the kinase domain (exons 18−21) have also been established as oncogenic drivers of non–small cell lung cancer (NSCLC) and confer different sensitivity or resistance to EGFR TKIs.[6] Patients with uncommon EGFR mutations show heterogeneity.